FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN, L2
Annual Report to Security Holders
Director Departure - Anne O’Riordan Will Not Stand for Re-Election
Announces First Quarter 2026 Financial Results
Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
January 2026 44th Annual Healthcare Conference Redefining Possibilities in Rare Disease
HERIZON-GEA-01 Phase 3 Results Favor Ziihera® as First-Line HER2-Targeted Therapy in Advanced Gastroesophageal Cancer
Financial Results, Press Release
Dr. Ted Love Appointed to Jazz Pharmaceuticals Board of Directors
Q1
Amended Annual Report
FY 2024
Q3
Q2
FY 2023
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
Amended Tender Offer Statement by Third Party